Tuesday, July 27, 2021 2:38:09 PM
If it was up to me, I would probably stop providing lenz to the NIH for their Activ5 trial.
I would appeal the NIH's finding that there was insufficient evidence for them to specifically recommend lenz as a GM-CSF inhibitor, and that Humanigen was treated unjustly by a collective determination which included inferior GM-CSF inhibitors.
I would dispute the Key Limitations they cited. Our study was powered to meet the evolving endpoint the FDA was recommending. I think the HHS OIG should look into why there were differences in supportive care in our study sites, and whether those differences should have resulted in a decrease of our Hazard Ratio rating.
https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/table-of-contents/
https://www.covid19treatmentguidelines.nih.gov/tables/table-4b/
The FDA should not be deterred in making a decision to approve an EUA for lenz, just because the Otilimab and Mavrilimumab mAbs collectivley caused the NIH to determine there was insufficient evidence to render a GM-CSF group recommendation.
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM